Retatrutide, a new dual agonist of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising data in preliminary human studies. Ongoing research implies https://atozbookmarkc.com/story21579748/retatrutide-emerging-research-and-projected-medical-uses